1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Esclerosis Múltiple

Esclerosis Múltiple

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD.

    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.

    JOURNAL OF NEUROLOGY . 272(1): 26-26.

    [doi:10.1007/s00415-024-12763-w]

  • Sainz-Amo R, Rodero-Romero A, Monreal E, Chico-García JL, Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Veiga-González JL, de la Maza SS, Masjuan J, Costa-Frossard L, Villar LM.

    Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(23): .

    [doi:10.3390/ijms252313153]

  • Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM.

    Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

    Brain . 147(12): 4084-4093. Nº de citas: 2

    [doi:10.1093/brain/awae260]

  • Meca-Lallana JE, Robles R, Landete L, Téllez N, García-Domínguez JM, Garcés P, Costa-Frossard L.

    A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.

    Cureus . 16(11): 74001-74001.

    [doi:10.7759/cureus.74001]

  • Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM.

    Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

    Frontiers in immunology . 15: 1480676-1480676.

    [doi:10.3389/fimmu.2024.1480676]

  • Aguirre C, Alonso-Torres A, Agüera E, García-Domínguez JM, Montero-Escribano P, González-Quintanilla V, Costa-Frossard L, Oreja-Guevara C, Reyes-Garrido V, Caminero-Rodríguez AB, Riancho J, Sánchez O, Forero L, Pérez-Parra F, Ares-Luque A, Téllez N, Arzalluz-Luque J, Iglesias F, Casado-Ruiz V, Castellano-Vicente AJ, Borrega L, Galán V, de Antonio LAR, Romero C, García-Rodríguez R, Cano-Orgaz AT, Sánchez-Menoyo JL, Pérez-Ruiz D, Gutiérrez-Martin F, Hernández-Echevarría L, Meca-Lallana V.

    Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

    CLINICAL DRUG INVESTIGATION . 44(11): 829-838.

    [doi:10.1007/s40261-024-01397-5]

  • Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE.

    Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS . 17: .

    [doi:10.1177/17562864241284372]

  • Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J.

    Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105787-105787.

    [doi:10.1016/j.msard.2024.105787]

  • Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB.

    Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 90: 105838-105838.

    [doi:10.1016/j.msard.2024.105838]

  • Domínguez-Mozo MI, Casanova I, Monreal E, Costa-Frossard L, Sainz-de-la-Maza S, Sainz-Amo R, Aladro-Benito Y, Lopez-Ruiz P, De-Torres L, Abellán S, Garcia-Martinez MA, De-la-Cuesta D, Lourido D, Torrado A, Gomez-Barbosa C, Linares-Villavicencio C, Villar LM, López-De-Silanes C, Arroyo R, Alvarez-Lafuente R.

    Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(18): .

    [doi:10.3390/ijms251810012]

  • Santas E, Villar S, Palau P, Llàcer P, de la Espriella R, Miñana G, Lorenzo M, Núñez-Marín G, Górriz JL, Carratalá A, Rodríguez E, Bayes-Genís A, Sanchis J, Núñez J.

    High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure.

    SCIENTIFIC REPORTS . 14(1): 21672-21672.

    [doi:10.1038/s41598-024-72137-0]

  • Navarrete-Pérez A, Gómez-Melero S, Escribano BM, Galvao-Carmona A, Conde-Gavilán C, Peña-Toledo MÁ, Villarrubia N, Villar LM, Túnez I, Agüera-Morales E, Caballero-Villarraso J.

    MIND Diet Impact on Multiple Sclerosis Patients: Biochemical Changes after Nutritional Intervention.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(18): .

    [doi:10.3390/ijms251810009]

  • Tortosa-Carreres J, Cubas-Núñez L, Piqueras M, Castillo-Villalba J, Quintanilla-Bordàs C, Quiroga-Varela A, Villarrubia N, Monreal E, Álvarez G, Gasque-Rubio R, Forés-Toribio L, Carratalà-Boscà S, Lucas C, Sanz MT, Ramió-Torrentà L, Villar LM, Casanova B, Laiz B, Pérez-Miralles FC.

    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

    JOURNAL OF NEUROIMMUNOLOGY . 394: 578428-578428.

    [doi:10.1016/j.jneuroim.2024.578428]

  • Di Filippo M, Gaetani L, Centonze D, Hegen H, Kuhle J, Teunissen CE, Tintoré M, Villar LM, Willemse EAJ, Zetterberg H, Parnetti L.

    Fluid biomarkers in multiple sclerosis: from current to future applications.

    LANCET REGIONAL HEALTH-EUROPE . 44: 101009-101009. Nº de citas: 1

    [doi:10.1016/j.lanepe.2024.101009]

  • Chico-Garcia, Juan Luis, Amo, Raquel Sainz, Monreal, Enric, de la Maza, Susana Sainz, Jorge, Fernando Rodriguez, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa Maria.

    Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study

    MULTIPLE SCLEROSIS JOURNAL . 30(10): 1239-1349.

    [doi:10.1177/13524585241272960]

  • Sainz de la Maza S, Rodero-Romero A, Monreal E, Chico-García JL, Villarrubia N, Rodríguez-Jorge F, Fernández-Velasco JI, Sainz-Amo R, Costa-Frossard L, Masjuan J, Villar LM.

    COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.

    Frontiers in immunology . 15: 1439393-1439393.

    [doi:10.3389/fimmu.2024.1439393]

  • Sainz-Amo R, Rodero Romero A, Monreal E, Chico García JL, Fernández Velasco JI, Villarrubia N, Veiga González JL, Sainz de la Maza S, Rodríguez Jorge F, Masjuan J, Costa-Frossard L, Villar LM.

    Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

    Frontiers in immunology . 15: 1454474-1454474.

    [doi:10.3389/fimmu.2024.1454474]

  • Rodero-Romero A, Monreal E, Sainz-Amo R, García Domínguez JM, Villarrubia N, Veiga-González JL, Fernández-Velasco JI, Goicochea-Briceño H, Rodríguez-Jorge F, Sainz de la Maza S, Chico-García JL, Muriel A, Masjuan J, Costa-Frossard L, Villar LM.

    Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 25(14): .

    [doi:10.3390/ijms25147808]